title: Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
abstract: Currently, there are few studies that address the prognostic significance of baseline additional chromosomal abnormalities (ACAs) in newly diagnosed acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO) as the front-line therapy. A series of 271 consecutive APL patients has been cytogenetically investigated between 2004 and 2011 in our institution. The incidence of ACAs was 27% (46/172) in APL cases with t(15;17). Trisomy 8 was the most recurrent abnormality, accounting for 30% (14/46) of patients with ACAs, followed by +21 (7%, 3/46) and -7/7q (7%, 3/46). Nine cases (14.1%) were found to have additional balanced translocation aberrations, most of them are new and non-recurrent. Treatment protocols consisted of all-trans retinoic acid (ATRA) and chemotherapy with or without the ATO therapy. Overall, patients with and without ACAs had similar complete remission (CR) rates (94% and 98%, respectively, P=0.344). With a median follow-up of 41 months, univariate analysis showed that ACAs did not show any prognostic significance in relapse-free survival (RFS) and overall survival (OS). In addition, ATO treatment was an independent favorable predictor for RFS. Thus, this data provides insights into cytogenetic features of APL, and suggests that ATO-based combination therapy improved RFS in de novo APL patients, while ACAs had no impact on prognosis.
authors: Department of Hematology, Institute of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, PR China.
authors: Yinjun
authors: Y
authors: Lou
authors: Shanshan
authors: S
authors: Suo
authors: Hongyan
authors: H
authors: Tong
authors: Xingnong
authors: X
authors: Ye
authors: Yungui
authors: Y
authors: Wang
authors: Zhimei
authors: Z
authors: Chen
authors: Wenbin
authors: W
authors: Qian
authors: Haitao
authors: H
authors: Meng
authors: Wenyuan
authors: W
authors: Mai
authors: Jian
authors: J
authors: Huang
authors: Yin
authors: Y
authors: Tong
authors: Jie
authors: J
authors: Jin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000235:genetics*; D002869:Chromosome Aberrations; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D009367:Neoplasm Staging; D010087:Oxides / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014178:Translocation, Genetic / Q000235:genetics; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001152:Arsenicals; D014408:Biomarkers, Tumor; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
keywords: Acute promyelocytic leukemia; Additional cytogenetic abnormalities; Arsenic trioxide; Prognosis